期刊文献+

Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo 被引量:2

Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo
下载PDF
导出
摘要 OBJECTIVE: To investigate the effect of somatostatin analogue octreotide on angiogenesis induced byhepatocellular carcinoma (HCC) in vivo.METHODS: LCI-D20 corneal micropocket model in nude mouse was used to dynamically observeangiogenesis under a stereoscopic zoom microscope and a digital camera system and to evaluate the effectof octreotide on angiogenesis. Male nude mice were subcutaneously implanted with LCI-D20 tumor tissuesfor tumor xenograft studies. Microvessel density in CD34-stained tumor sections was analyzed byimmunohistochemical SP method.RESULTS: Tumor tissues from LCI-D20 implanted into the corneal micropocket induced angiogenesis.When animals received systemic octreotide treatment, angiogenesis response in the cornea of mice wasmoderate, the appearance of vascular buds was delayed, and the new capillaries were sparse and grewslowly. Compared with the control group, the neovascularization induced by HCC in the cornea of micewas markedly inhibited on day 7, 9, 12, 15, 18 and 21 after implantation in the octreotide-treated group(P【0.05). Systemic administration of octreotide produced a significant suppression of the growth ofLCI-D20. Immunohistochemical studies of tumor tissues revealed decreased microvessel density in theoctreotide-treated animals as compared with the controls (21.7±4.27 versus 31.8±3.87, P【0. 01).CONCLUSION: Somatostatin analogue octreotide is able to inhibit angiogenesis induced by HCC invivo and may provide a new approach to the treatment of HCC.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2003年第3期404-409,共6页 国际肝胆胰疾病杂志(英文版)
基金 This study was supported by a grant from the Natural Science Foundation of Anhui (No.01043708).
  • 相关文献

参考文献2

二级参考文献1

共引文献20

同被引文献13

  • 1谢咏梅,严律南,魏兵,郭梅梅,唐承薇.原发性肝癌患者肿瘤组织生长抑素受体表达与血AFP水平的相关性[J].癌症,2007,26(7):688-692. 被引量:6
  • 2沈中阳.将健康传播更远——重视我国肝脏移植受者的远期预后[J].中国危重病急救医学,2007,19(7). 被引量:7
  • 3Imamura H,Matsuyama Y,Tanaka E. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J].Journal of Hepatology,2003,(02):200-207.
  • 4Williams R. Global challenges in liver disease[J].Hepatology,2006,(03):521-526.
  • 5Plentz RR,Tillmann HL,Kubicka S. Hepatocellular carcinoma and octreotide:treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage[J].Journal of Gastroenterology and Hepatology,2005,(09):1422-1428.doi:10.1111/j.1440-1746.2005.03959.x.
  • 6Kharmate G,Rajput PS,Watt HL. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling[J].Biochimica Et Biophysica Acta,2011,(06):1172-1189.
  • 7Xie Y,Chen S,Wang CH. SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts[J].Cancer Biology and Therapy,2011,(01):86-92.
  • 8Hasskarl J,Kaufmann M,Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies:the potential role of somatostatin analogs in solid tumors[J].FUTURE ONCOLOGY,2011,(07):895-913.
  • 9苗雄鹰,文宇,胡继雄,戴卫东.肝癌术后早期复发临床危险因素的分析[J].中华肿瘤防治杂志,2009,16(3):219-221. 被引量:17
  • 10沈中阳.正视发展中的中国肝脏移植[J].中国危重病急救医学,2010(1):2-3. 被引量:7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部